Constructing access in predictive medicine. Comparing classification for hereditary breast cancer risks in England, Germany and the Netherlands

Social Science and Medicine

Volumn 72, Issue 4, 2011, Pages 553-559

  Aarden, Erik ^a   Van Hoyweghen, Ine ^a   Horstman, Klasien ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Access; Access to care; Breast cancer; England; Genetics; Germany; Health care; Predictive medicine; The Netherlands

Indexed keywords

CANCER; CLASSIFICATION; COMPARATIVE STUDY; GENETICS; HEALTH CARE; HEALTH RISK; MEDICINE; QUALITATIVE ANALYSIS; RISK ASSESSMENT;

ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SUSCEPTIBILITY; CLASSIFICATION; FAMILIAL CANCER; FAMILY HISTORY; GENETIC SCREENING; GERMANY; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEREDITARY BREAST CANCER; MEDICINE; NETHERLANDS; QUALITATIVE RESEARCH; RISK ASSESSMENT; UNITED KINGDOM; ANAMNESIS; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HEALTH CARE DELIVERY; HEALTH SERVICES RESEARCH; HUMAN; ORGANIZATION AND MANAGEMENT;

ENGLAND; GERMANY; NETHERLANDS; UNITED KINGDOM;

BREAST NEOPLASMS; DELIVERY OF HEALTH CARE; ENGLAND; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERMANY; HEALTH SERVICES ACCESSIBILITY; HUMANS; MEDICAL HISTORY TAKING; NETHERLANDS; ORGANIZATIONAL CASE STUDIES; QUALITATIVE RESEARCH; RISK ASSESSMENT;

EID: 79954441455     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2010.11.033     Document Type: Article

References (50)

1. Bärnighausen T., Sauerborn R. One hundred and eighteen years of the German health insurance system: are there any lessons for middle- and low-income countries?. Social Science & Medicine 2002, 54:1559-1587.
2. Berg M. Rationalizing medical work. Decision support techniques and medical practices 1997, The MIT Press, Cambridge, MA.
3. Boenink M. Genetic diagnostics for hereditary breast cancer: Displacement of uncertainty and responsibility. Genetics from laboratory into society. societal learning as an alternative to regulation 2008, Palgrave Macmillan, Basingstoke. G. De Vries, K. Horstman (Eds.).
4. Bouchard L., Blancquaert I., Eisinger F., Foulkes W., Evans G., Sobol H., et al. Prevention and genetic testing for breast cancer: variations in medical decisions. Social Science & Medicine 2004, 58:1085-1096.
5. Bowker G., Star S.L. Sorting things out. Classification and its consequences 1999, The MIT Press, Cambridge, MA.
6. Boyle P. Genetic services, social context, and public priorities. Technoscience and cyberculture 1996, 205-211. Routledge, New York. S. Aronowitz, B. Martinsons, M. Menser (Eds.).
7. Richtlinien zur Diagnostik der genetischen Disposition für Krebserkrankungen. Deutsches Ärzteblatt 1998, 95(22):1396-1403. Bundesärztekammer.
8. Burau V., Blank R. Comparing health policy: an assessment of typologies of health systems. Journal of Comparative Policy Analysis 2006, 8(1):63-76.
9. Calnan M., Wainwright D., Glasner P., Newbury-Ecob R., Ferlie E. 'Medicine's Next Goldmine?' The implications of new genetic health technologies for the health service. Medicine, Health Care and Philosophy 2006, 9:33-41.
10. Chapman D. Cancer genetics. Seminars in Oncology Nursing 2007, 23(1):2-9.
11. Coventry P., Pickstone J. From what and why did genetics emerge as a medical specialism in the 1970s in the UK? A case-history of research, policy and services in the Manchester region of the NHS. Social Science & Medicine 1999, 49:1227-1238.
12. Beoordeling stand van de wetenschap en praktijk 2007, CvZ, College voor Zorgverzekeringen, Diemen.
13. Genetics from laboratory to society. Societal learning as an alternative to regulation 2008, Palgrave Macmillan, Basingstoke. G. De Vries, K. Horstman (Eds.).
14. Department of Health Our Inheritance, our future. Realising the potential of genetics in the NHS 2003, Department of Health, London.
15. Doyal L., Doyal L. The British National Health Service: a tarnished moral vision?. Health Care Analysis 1999, 7:363-376.
16. Evans J., Skrzynia C., Burke W. The complexities of predictive genetic testing. British Medical Journal 2001, 322:1052-1056.
17. Foulkes W. Inherited susceptibility to common cancers. New England Journal of Medicine 2008, 359(20):2143-2153.
18. Stellungnahme zur Entdeckung des Brustkrebsgens BRCA1. Medizinische Genetik 1995, 7:8-10. Gesellschaft für Humangenetik.
19. Gibbon S. Re-examining geneticization: family trees in breast cancer genetics. Science as Culture 2002, 11(4):429-457.
20. Goodwin J., Horowitz R. Introduction: the methodological strengths and dilemmas of qualitative sociology. Qualitative Sociology 2002, 25(1):33-47.
21. Gress S., Niebuhr D., Rothgang H., Wasem J. Criteria and procedures for determining benefit packages in health care. A comparative perspective. Health Policy 2005, 73(1):78-91.
22. Holtzman N., Marteau T. Will genetics revolutionize medicine?. New England Journal of Medicine 2000, 343:141-144.
23. Hopkins M., Martin P., Nightingale P., Kraft A., Mahdi S. The Myth of the Biotech revolution: an assessment of technological, clinical and organisational change. Research Policy 2007, 36:566-589.
24. Jasanoff S. States of knowledge. The co-production of science and social order. International library of sociology 2004, Routledge, London. J. Urry (Ed.).
25. Kröner H. Der Einfluss der deutschen Atomkommission ab 1955 auf die Biowissenschaften. Wissenschaften und Wissenschaftspolitik. Bestandsaufnahmen zu Formationen, Brüchen und Kontinuitäten im Deutschland des 20. Jahrhunderts 2002, Franz Steiner Verlag, Stuttgart. R. Vom Bruch, B. Kaderas (Eds.).
26. Lameire N., Joffe P., Wiedemann M. Healthcare systems - an international review: an overview. Nephrology Dialysis Transplantation 1999, 14(Suppl 6):3-9.
27. Latour B. Pandora's hope. Essays on the reality of science studies 1999, Harvard University Press, Cambrdige, MA.
28. Löwy I., Gaudillière J. Localizing the global: testing for hereditary risks of breast cancer. Science, Technology, & Human Values 2008, 33(3):299-325.
29. MacDonald A. Genetics and insurance: what have we learned so far?. Scandinavian Actuarial Journal 2003, 324-348.
30. Nelis A. DNA-diagnostiek in Nederland. Een regime-analyse van de ontwikkeling van de klinische genetica en DNA-diagnostische tests, 1970-1997 1998, Twente University Press, Enschede.
31. Nelkin D., Tancredi L. Dangerous diagnostics. The social power of biological information 1989, The University of Chicago Press, Chicago.
32. Familial breast cancer. The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care 2006, NICE, Clinical Guideline 14, National Institute for Health and Clinical Excellence, London.
33. Oliver A. The English National Health Service: 1979-2005. Health Economics 2005, 14:S75-S99.
34. Parthasarathy S. Building genetic medicine. Breast cancer, technology and the comparative politics of health care 2007, The MIT Press, Cambridge, MA.
35. Payer L. Medicine & Culture: Notions of health and sickness in Britain, the U.S., France and West-Germany 1990, Gollancz, London.
36. Perpich J. The dawn of genomic and regenerative medicine: new paradigms for medicine, the public's health, and society. Technology in Society 2004, 26:405-414.
37. Petersen A., Lupton D. The New public health. Health and self in the age of risk 1996, Sage, London.
38. Prior L. Rationing through risk assessment in clinical genetics: all categories have wheels. Sociology of Health & Illness 2001, 23(5):570-593.
39. Schmutzler R., Löffler M., Windeler J., Thomas S., Bruns J., Rath T. Familiärer Brust- und Eierstockkrebs. Von der Forschung zur Regelversorgung. Deutsches Ärzteblatt 2006, 102(50):3486-3488.
40. Schut F. Health care reform in the Netherlands: balancing corporatism, etatism, and market mechanisms. Journal of Health Politics, Policy & Law 1995, 20(3):615-652.
41. Shakespeare T. Disability, genetics and global justice. Social Policy & Society 2005, 4(1):87-95.
42. Erfelijke Tumoren: Richtlijnen voor diagnostiek en preventie 2005, STOET, Vereniging Klinische Genetica Nederland Werkgroep Klinische OncogeneticaVereniging Klinische Genetica Nederland Werkgroep Klinische Oncogenetica.
43. Van de Ven W., Schut F. Universal mandatory health insurance in the Netherlands: a model for the United States?. Health Affairs 2008, 27(3):771-781.
44. Van der Zee J., Kroneman M. Bismarck or beveridge: a beauty contest between dinosaurs. BMC Health Services Research 2007, 7(94).
45. Van Hoyweghen I. Genetics and insurance: New technologies, new policies, new responsibilities. Genetics from laboratory to society. Societal learning as an alternative to regulation 2008, Palgrave Macmillan, Basingstoke. G. De Vries, K. Horstman (Eds.).
46. Varmus H. Getting ready for gene-based medicine. New England Journal of Medicine 2002, 347(19):1526-1527.
47. Vasen H., Griffioen G., Lips C., Van Slooten E. De waarde van screening en landelijke registratie van erfelijke tumoren. Nederlands Tijdschrift voor Geneeskunde 1988, 132(35):1609-1612.
48. Weinshilboum R. The genomic revolution and medicine. Mayo Clinic Proceedings 2002, 77(8):745-746. Editorial.
49. Wiesing U. Die Bedeutung der Genetik für die Krankenversicherung. Deutsche Medizinische Wochenschrift 2002, 127(21):1151-1154.
50. Wooster R., Weber B. Breast and ovarian cancer. New England Journal of Medicine 2003, 348(23):2339-2347.